Most abundant proteins in COBRA venom; basic polypeptides of 57 to 62 amino acids with four disulfide bonds and a molecular weight of less than 7000; causes skeletal and cardiac muscle contraction, interferes with neuromuscular and ganglionic transmission, depolarizes nerve, muscle and blood cell membranes, thus causing hemolysis.
A family of extremely venomous snakes, comprising coral snakes, cobras, mambas, kraits, and sea snakes. They are widely distributed, being found in the southern United States, South America, Africa, southern Asia, Australia, and the Pacific Islands. The elapids include three subfamilies: Elapinae, Hydrophiinae, and Lauticaudinae. Like the viperids, they have venom fangs in the front part of the upper jaw. The mambas of Africa are the most dangerous of all snakes by virtue of their size, speed, and highly toxic venom. (Goin, Goin, and Zug, Introduction to Herpetology, 3d ed, p329-33)
Venoms from snakes of the genus Naja (family Elapidae). They contain many specific proteins that have cytotoxic, hemolytic, neurotoxic, and other properties. Like other elapid venoms, they are rich in enzymes. They include cobramines and cobralysins.
Venoms from snakes of the family Elapidae, including cobras, kraits, mambas, coral, tiger, and Australian snakes. The venoms contain polypeptide toxins of various kinds, cytolytic, hemolytic, and neurotoxic factors, but fewer enzymes than viper or crotalid venoms. Many of the toxins have been characterized.
Agents that have a damaging effect on the HEART. Such damage can occur from ALKYLATING AGENTS; FREE RADICALS; or metabolites from OXIDATIVE STRESS and in some cases is countered by CARDIOTONIC AGENTS. Induction of LONG QT SYNDROME or TORSADES DE POINTES has been the reason for viewing some drugs as cardiotoxins.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
The level of protein structure in which regular hydrogen-bond interactions within contiguous stretches of polypeptide chain give rise to alpha helices, beta strands (which align to form beta sheets) or other types of coils. This is the first folding level of protein conformation.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain).
A live VACCINIA VIRUS vaccine of calf lymph or chick embryo origin, used for immunization against smallpox. It is now recommended only for laboratory workers exposed to smallpox virus. Certain countries continue to vaccinate those in the military service. Complications that result from smallpox vaccination include vaccinia, secondary bacterial infections, and encephalomyelitis. (Dorland, 28th ed)
Inflammation of the PERICARDIUM from various origins, such as infection, neoplasm, autoimmune process, injuries, or drug-induced. Pericarditis usually leads to PERICARDIAL EFFUSION, or CONSTRICTIVE PERICARDITIS.
Systems developed for collecting reports from government agencies, manufacturers, hospitals, physicians, and other sources on adverse drug reactions.
The activities and endeavors of the public health services in a community on any level.
An acute, highly contagious, often fatal infectious disease caused by an orthopoxvirus characterized by a biphasic febrile course and distinctive progressive skin eruptions. Vaccination has succeeded in eradicating smallpox worldwide. (Dorland, 28th ed)
A species of ORTHOPOXVIRUS causing infections in humans. No infections have been reported since 1977 and the virus is now believed to be virtually extinct.
Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.

Skeletal myogenesis by human embryonic stem cells. (1/115)

We have examined the myogenic potential of human embryonic stem (hES) cells in a xeno-transplantation animal model. Here we show that precursors differentiated from hES cells can undergo myogenesis in an adult environment and give rise to a range of cell types in the myogenic lineage. This study provides direct evidences that hES cells can regenerate both muscle and satellite cells in vivo and are another promising cell type for treating muscle degenerative disorders in addition to other myogenic cell types.  (+info)

Beta-cardiotoxin: a new three-finger toxin from Ophiophagus hannah (king cobra) venom with beta-blocker activity. (2/115)

Snake venoms have provided a number of novel ligands with therapeutic potential. We have constructed a partial cDNA library from the mRNA of Ophiophagus hannah (king cobra) venom gland tissue and identified five new genes encoding proteins belonging to the three-finger toxin family of snake venom proteins. We have isolated and characterized one of these beta-sheet containing proteins with a mass of 7012.43 +/- 0.91 Da from the venom. The protein was nonlethal up to a dose of 10 mg/kg when injected intraperitoneally into Swiss albino mice. However, it induces labored breathing and death at a dose of 100 mg/kg. It does not show any hemolytic or anticoagulant activity. It caused a dose-dependent decrease of heart rate in vivo (anesthetized Sprague-Dawley rats) and also ex vivo (Langendorff isolated rat heart). This is in contrast to classical cardiotoxins from snake venom that increase the heart rate in animals. Radioligand displacement studies showed that this protein targets beta-adrenergic receptors with a binding affinity (Ki) of 5.3 and 2.3 microM toward beta1 and beta2 subtypes, respectively, to bring about its effect, and hence, it was named as beta-cardiotoxin. This is the first report of a natural exogenous beta-blocker.  (+info)

Functional analysis of homeodomain-containing transcription factor Lbx1 in satellite cells of mouse skeletal muscle. (3/115)

Satellite cells are usually mitotically quiescent muscle stem cells, located between the sarcolemma and the basement membrane of muscle fibers. When muscles are damaged, satellite cells become activated, proliferate and differentiate to form multinucleate myofibers. The molecular mechanisms underlying these processes are poorly understood. In the present study, we found that, following treatment with cardiotoxin, homeodomain-containing transcription factor Lbx1 was strongly expressed in the satellite cells of regenerating adult skeletal muscle. Our immunohistochemical and northern blot analyses indicate that Lbx1 is expressed in activated but not quiescent satellite cells. In vitro, this Lbx1 expression was gradually downregulated when satellite cells differentiate into mature myofibers. Transfection and forced expression of Lbx1 in satellite-cell-derived C2C12 myoblast cells resulted in severe depression of myogenic differentiation and incomplete myotube formation, concomitantly with the activation of the paired-box transcription factor Pax7 and depression of the myogenic regulatory factor MyoD. Moreover, knockdown of Lbx1 in in-vitro-cultured satellite cells resulted in downregulation of Pax7. These results suggest that Lbx1 plays important roles in differentiation and maintenance of satellite cells of mature myofibers, probably through the regulation of Pax7.  (+info)

Structural reengineering of imatinib to decrease cardiac risk in cancer therapy. (4/115)

Imatinib, a selective, small-molecule tyrosine kinase inhibitor, has life-saving clinical activity in certain cancers, but questions have been raised about the potential for cardiac toxicity through inhibition of its target, ABL kinase. In this issue of the JCI, Fernandez et al. describe a novel method by which the ABL-inhibitory activity of imatinib was deleted by modifying its chemical structure (see the related article beginning on page 4044). The anticancer activity of the reengineered agent, called WBZ_4, was instead preserved against gastrointestinal stromal tumors in both in vitro and in vivo models via inhibition of KIT tyrosine kinase, and the desired safety was demonstrated with less cardiotoxicity of WBZ_4 compared with imatinib via the inhibition of JNK. The study shows that structural reengineering of a kinase-inhibitory drug to improve tolerability while preserving efficacy is feasible.  (+info)

An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. (5/115)

Targeting kinases is central to drug-based cancer therapy but remains challenging because the drugs often lack specificity, which may cause toxic side effects. Modulating side effects is difficult because kinases are evolutionarily and hence structurally related. The lack of specificity of the anticancer drug imatinib enables it to be used to treat chronic myeloid leukemia, where its target is the Bcr-Abl kinase, as well as a proportion of gastrointestinal stromal tumors (GISTs), where its target is the C-Kit kinase. However, imatinib also has cardiotoxic effects traceable to its impact on the C-Abl kinase. Motivated by this finding, we made a modification to imatinib that hampers Bcr-Abl inhibition; refocuses the impact on the C-Kit kinase; and promotes inhibition of an additional target, JNK, a change that is required to reinforce prevention of cardiotoxicity. We established the molecular blueprint for target discrimination in vitro using spectrophotometric and colorimetric assays and through a phage-displayed kinase screening library. We demonstrated controlled inhibitory impact on C-Kit kinase in human cell lines and established the therapeutic impact of the engineered compound in a novel GIST mouse model, revealing a marked reduction of cardiotoxicity. These findings identify the reengineered imatinib as an agent to treat GISTs with curbed side effects and reveal a bottom-up approach to control drug specificity.  (+info)

Comparative genomics identifies genes mediating cardiotoxicity in the embryonic zebrafish heart. (6/115)

 (+info)

Atrial dysfunction as a marker of iron cardiotoxicity in thalassemia major. (7/115)

 (+info)

Mechanisms responsible for reduced cardiotoxicity of mitoxantrone compared to doxorubicin examined in isolated guinea-pig heart preparations. (8/115)

We reported previously that doxorubicin, an anticancer agent that has an anthracycline structure, alters Ca2+ releasing and uptake mechanisms in the sarcoplasmic reticulum of myocardial cells. These effects of doxorubicin are apparently related to its cardiotoxicity. Mitoxantrone is a similar anticancer agent with an anthracenedion structure that has been shown to be significantly less cardiotoxic. In the present study, the effects of mitoxantrone on the functions of the sarcoplasmic reticulum were examined in isolated muscle preparations obtained from the guinea-pig heart. In electrically-stimulated left atrial muscle preparations, incubation in vitro for 4 hr with 30 or 100 microM mitoxantrone significantly prolonged the time to the peak of twitch tension, markedly increased the developed tension observed at lower stimulation frequencies, thereby attenuating the slope of positive force-frequency relationships, and increased the postrest contraction observed after a 60-sec quiescent period. In myocytes isolated from ventricular muscles, 30 microM mitoxantrone increased the peak and the size of intracellular Ca2+ concentrations ([Ca2+] i), and prolonged the time to peak [Ca2+]i. In skinned muscle fiber preparations obtained from the left ventricular muscle, 30 muM mitoxantrone significantly increased the caffeine-induced contraction without affecting the Ca2+ sensitivity of contractile proteins. These results suggest that mitoxantrone enhances Ca2+ release from the sarcoplasmic reticulum in isolated atrial muscle preparations obtained from the guinea-pig heart. Apparent enhancement of the sarcoplasmic reticulum functions, in contrast to anthracyclines that has been shown to suppress these functions, seems to explain the relative lack of marked cardiotoxicity of mitoxantrone.  (+info)

TY - CHAP. T1 - Cardiotoxic Effects of Anti-VEGFR Tyrosine Kinase Inhibitors. AU - Novo, Giuseppina. AU - Russo, Antonio. AU - Galvano, Antonio. AU - Bronte, Enrico. PY - 2016. Y1 - 2016. N2 - Angiogenesis is a key moment in tumor development and proliferation. Until recently oncologists did not know the mechanisms that were behind this phenomenon, but following the discoveries of Folkman and coworkers, they have gradually created and developed a series of drugs that act against angiogenesis by interacting with molecules belonging to the vascular endothelial growth factor (VEGFs) class and its receptors (VEGFRs) giving rise to anticancer effects. Tyrosine kinase inhibitors (TKIs) are a major class of these new anticancer agents, demonstrating high antitumor activity in a variety of orphan neoplasms (such as hepatocellular carcinoma, kidney cancer, sarcomas, etc.). The mechanism of action of these drugs also explains their toxicity profile with respect to the cardiovascular system. The aim of ...
Molodavkin G.M.; Sorokina A.V.; Yavorskii A.N.; Lyubimov B.I.; Burov Y.V., 1986: The electrophysiological and morphological analysis of the cardiotoxic effect of ethanol in rats
Cardiotoxicity is a condition when there is damage to the heart muscle. It may be caused by chemotherapy drugs or medications concerning other diseases. As a result of cardiotoxicity, the heart becomes weaker and is unable to pump blood throughout the body.. DelveInsights Cardiotoxicity Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Cardiotoxicity, historical and forecasted epidemiology as well as the Cardiotoxicity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.. Some Key Highlights from the Cardiotoxicity Market Report:. ...
Cardiotoxicity is a condition when there is damage to the heart muscle. It may be caused by chemotherapy drugs or medications concerning other diseases. As a result of cardiotoxicity, the heart becomes weaker and is unable to pump blood throughout the body.. DelveInsights Cardiotoxicity Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Cardiotoxicity, historical and forecasted epidemiology as well as the Cardiotoxicity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.. Some Key Highlights from the Cardiotoxicity Market Report:. ...
The cardiac effects of treatment for malignancy are likely to become an increasing problem over the coming decades. This issue is multifactorial and reflects the evolution of cancer from a malignant illness to a chronic disease, as well as the widespread use of cardiotoxic agents. Two groups of patients seem to be especially at risk. In survivors of childhood cancer, the risk for recurrence or progression of malignancy rapidly diminishes after a decade, and cardiac complications are the main cause of cancer-related mortality that is unrelated to recurrence (1). In adults, several of the most common malignancies (especially breast cancer and lymphoma) are often treated with anthracyclines and/or radiotherapy (2). Breast cancer is the most common source of cardiac problems, reflecting its frequency, the cardiotoxic effects of specific chemotherapy, and the consequences of radiation to the left breast. Improvements in detection and therapy have led to ,2 million American women who will have ...
A look at the following clinical trial: Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment (PREDICT)
hERG assay is used for screening of compounds acting as potential ligands or blockers of hERG channel which is an indication for cardiotoxicity.
3Ton Hydraulic Trolley Jack-Changshu Tongrun Auto Accessory Co., ltd-• The hydraulic technology makes lifting simple while a wider frame and internal bypass valve ensure safety.|br| • Safety bypass system prevents over-loading and ensures safe operation.|br| • Steel casters for longevity.
PMID- 29303721 OWN - NLM STAT- MEDLINE DCOM- 20180110 LR - 20180110 IS - 1474-547X (Electronic) IS - 0140-6736 (Linking) VI - 390 IP - 10114 DP - 2018 Dec 23 TI - Concerns about cardiotoxicity in the HERA trial. PG - 2767 LID - S0140-6736(17)31954-2 [pii] LID - 10.1016/S0140-6736(17)31954-2 [doi] FAU - Levy, Antonin AU - Levy A AD - Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif 94800, France; Faculte de Medecine, Universite Paris-Saclay, Kremlin Bicetre, France; INSERM U1030, Molecular Radiotherapy, Gustave Roussy Cancer Campus, Villejuif, France. Electronic address: [email protected] FAU - Chargari, Cyrus AU - Chargari C AD - Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif 94800, France; Faculte de Medecine, Universite Paris-Saclay, Kremlin Bicetre, France; INSERM U1030, Molecular Radiotherapy, Gustave Roussy Cancer Campus, Villejuif, France; Institut de Recherche Biomedicale des Armees, Bretigny sur Orge, France. FAU - Deutsch, Eric AU - ...
5-Fluorouracil is a key element to the treatment of colon cancer. But it is also one of the most cardiotoxic chemotherapies, and the management of those th
Greenmedinfo.com - Natural Health Resource - The worlds most widely referenced, open access, natural medicine database, with 30,000+ study abstracts and growing daily
by Jon Cole and Meghan Spyres Photo by Chris Benseler on Flickr Jon: Meghan, thank you for joining me on this post. Ive wanted to write about the
INTRODUCTION Our children are being relentlessly exposed to a cardiotoxic environment. High calorically dense, fat-enriched foods, and technologically aided
We have shown previously that PLNR9C leads to DCM, heart failure, and premature death in heterozygous humans and transgenic mice (PLN+/++TgPLNR9C).4 PLNR9C prevents phosphorylation of coexpressed PLNwt and thereby decelerates diastolic Ca2+ transport into the SR via SERCA2a (Figure 3A). Unlike the nearly normal inhibitory effect that is measured in transfected HEK-293 cells when PLNR9C is present together with PLNwt, SERCA2a inhibition by PLNR9C alone is weak (Figure 3C and 3E). Thus, cardiomyocyte expression of PLNR9C alone (PLN−/−+TgPLNR9C) results in SR Ca2+ uptake rates that are faster than those in wild-type myocytes and almost as fast as those in PLN−/− myocytes (Figure 3A and 3C). The acceleration of SR Ca2+ reuptake kinetics as a result of PLNwt ablation was accompanied by an improved morphological and functional phenotype of the hearts (Figures 1 and 2⇑); lower expression of atrial natriuretic peptide, brain natriuretic peptide, and β-myosin heavy chain (Figure IC of the ...
OncologyPRO is the home of ESMOs educational & scientific resources, with exclusive content for ESMO members such as ESMOs Congresses webcasts,
This 2012 Cardiovascular Research paper by J Ma, etc utilizes the following products and services from Vector Biolabs: Rho family, small GTP binding protein Rac1 Adenovirus, b-gal/LacZ Adenovirus.
Cancer treatment with doxorubicin (DOX) can induce cumulative dose-dependent cardiotoxicity. Currently, there are no specific biomarkers that can identify patients at risk during the initial doses of chemotherapy. The aim of this study was to examine plasma cytokines/chemokines and potential cardiovascular biomarkers for the prediction of DOX-induced cardiotoxicity. Plasma samples were collected before (T0), and after the first (T1) and the second (T2) cycles of DOX-based chemotherapy of 27 breast cancer patients, including five patients who presented with ,10% decline of left ventricular ejection fraction (LVEF), five patients with LVEF decline of 5-10%, and 17 patients who maintained normal LVEF at the end of chemotherapy (240 mg/m2 cumulative dose of DOX from four cycles of treatment ...
Our quality TIMKEN NUP305E.TVP bearing is top in the world. We have large inventory now. Delivery time: 5-7days. NUP305E.TVP NUP305E.TVP NUP305E.TVP NUP305E.TVP NUP305E.TVP NUP305E.TVP NUP305E.TVP NUP305E.TVP NUP305E.TVP NUP305E.TVP NUP305E.TVP 4T-30305D 4T-30305D 4T-30305D 4T-30305D 4T-30305D 4T-30305D 4T-30305D 4T-30305D ... condition monitoring and technical supports. we can assure the quality of the SKF 7305 BECBP bearings we provide, ZENEO Bearings ...
Over the last 40 years, a significant advance has been made in the treatment of childhood and adult cancers. However, the increase of the survival rate points out medium- and long-term adverse effects that constitute a serious limitation for the quality of life in adults survived from a childhood ca …
Bitolterol mesylate (Tornalate) is a short-acting β2 adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and COPD. In these disorders there is a narrowing of the airways (bronchi and their ramifications) that carry air to the lungs. Muscle spasm and inflammation within the bronchi get worse this narrowing. Bitolterol relaxes the smooth muscles present continuously around the bronchi and bronchioles facilitating the flow of air through them. Bitolterol is a prodrug of colterol. It has a rapid onset of action (2-5 minutes) and may last up to 6-8 hours. The drug, alone or in co-administration with theophylline, doesnt show cardiotoxic effect. The U.S. Food and Drug Administration (FDA) approved bitolterol in December 1984. The drug was withdrawn from the market by Élan Pharmaceuticals in 2001. Nathan RA, Bodman SF, Storms WW, Mingo TS (June 1986). Bitolterol mesylate aerosol in adults with steroid-dependent asthma: a comparison with isoproterenol ...
Sunitinib -- a tyrosine-kinase inhibitor used to extend survival in patients with renal-cell carcinoma and gastrointestinal stromal tumors -- has cardiotoxic effects.
Abstract: Cardiotoxicity is unfortunately a common side effect of many modern chemotherapeutic agents. The mechanisms that underlie these detrimental effects
A case of congestive heart failure in a child with Wilms tumor treated with Adriamycin is presented and discussed. The role of Adriamycin in the production of cardiotoxicity is reviewed.
Cardiotoxicity of anthracycline in young breast cancer female patients: the possibility of detection of early cardiotoxicity by TDI
Cómo evaluar la presencia de TVP desde la Urgencia?, ¿Cansado que el traumatólogo te derive todo por sospecha de TVP?. De esta forma ahorraremos mucho tiempo a nuestros pacientes, sin mencionar el riesgo de dejar anticoagulación por la duda como estilan en algunos lugares ...
Cardiomyopathy is a clinical problem that occurs in the hearts of type 2 diabetic patients as well as cancer patients undergoing doxorubicin chemotherapy. The number of diabetic cancer patients is increasing but surprisingly the cardiac damaging effects of doxorubicin, a commonly used chemotherapeutic drug, on diabetic hearts have not been well-examined. As the signaling mechanisms of the doxorubicin-induced cardiomyopathy in type 2 diabetic heart are largely unknown, this study examined the molecular signaling pathways that are responsible for the doxorubicin-induced cardiotoxicity in type 2 diabetic hearts. Male 14- to 18-week-old db/db mice were used as the type 2 diabetic model, and age-matched non-diabetic db/+ mice served as controls. The db/+ non-diabetic and db/db diabetic mice were randomly assigned to the following groups: db/+CON, db/+DOX-5d, db/+DOX-7d, db/dbCON, db/dbDOX-5d, and db/dbDOX-7d. Mice assigned to doxorubicin (DOX) group were exposed to an intraperitoneal (i.p.) injection of DOX
2016 Annual Meeting: Extracellular Matrix Impregnated with Adipose Derived Stem Cells in Skeletal Muscle Regeneration following Volumetric Muscle Loss in a Murine Model
Nakamori S, Jang J, Tschabrunn CM, Pierce P, Goddu B, Rodriguez J, Ngo LH, Tung NM, Manning WJ, Nezafat R. Noncontrast CMR for Detecting Early Myocardial Tissue Injury in a Swine Model of Anthracycline-Induced Cardiotoxicity. JACC Cardiovasc Imaging. 2019 10; 12(10):2085-2087 ...
Anthracyclines, such as doxorubicin and idarubicin, remain an important class of chemotherapeutic agents. Unfortunately, their efficacy in treating cancer is limited by a cumulative dose-dependent cardiotoxicity, which can cause irreversible heart failure. In this review, we discuss the pathogenesis …
Wow guys thanks so much for your insight. Its so hard to know what to do. I keep reading articles about people that cannot loose weight. This is not our case. Im still struggling, I think that I am also over-loading my body Im eating all the time. At least every 2 hrs. If not I feel weak and angry. Its crazy I used to look at food and put weight on. Now I eat like a horse no kidding and nothing. Ive read article about the hunter- gatherer Paleo diet basically all organic. High in Protein, Meats, Fish, Eggs, Vegs, Fruits, Alomond milk (instead of Rice Milk). But this eliminates Rice, Patatoes and Dairy, Soy. Apparantely Celiacs that are not seeing any results just with Gluten free diets should try it. Another word of advice is to try taking a probiotic - i was using Florea you take it before eating as it helps build the intestine, and glutamine it helps promote recover. Ive noticed that the last few days since i run out i feel weaker. So try this. I know how you feel its a battle every day to ...
0014]Accordingly, the present disclosure relates to a method for predicting organ toxicity comprising steps of: listing of drug-induced organ injuries, obtaining molecular mechanisms of toxicity followed by tabulating underlying biochemical pathways of said drugs which precipitates organ injury, identifying biomolecules, inferring biochemical pathways and modeling kinetics of enzymes involved in these pathways to obtain a homeostatic in silico model, perturbing the model and designing assays to measure the perturbation, applying the assays to a chemical or set of chemicals to generate new assay data, and feeding the new assay data to the model for predicting toxicity and organ damage; a system for predicting organ toxicity said system comprising: storage element having list of drug-induced organ injury along with their molecular mechanisms of toxicity and underlying biochemical pathways, in silico model component configured to represent normal organ, in vitro assays designed to quantitatively ...
TKIs are a major class of cancer therapeutics, with revenues from these drugs annually reaching billions of dollars (19). However, many TKIs, like other chemotherapeutics, exhibit substantial cardiotoxicities (3). Our results demonstrate that hiPSC-CMs can assess TKI cardiotoxicity in a high-throughput fashion. We evaluated 21 FDA-approved TKIs using hiPSC-CMs derived from 11 healthy individuals and 2 patients receiving TKIs as cancer therapy. From the data obtained, we developed a cardiac safety index integrating TKI-induced cytotoxicity measurements, contractility assessments, and literature-reported TKI blood plasma concentrations in patients. We also validated the negative effects of known cardiotoxic TKIs.. Previous studies evaluated TKI cardiotoxicity using animals and other in vitro models (20). Sorafenib, one of the three most cytotoxic TKIs in our study, induces cardiomyocyte death and contractility defects in the zebrafish heart and causes ventricular dysfunction and heart failure ...
Thermal processing of meat products generates cardiotoxic compounds capable of inducing heart failure in both humans and laboratory animals. Such compounds may be present in broiler diets because supplements such as meat meal (MM), which are commonly
Aminoacridine derivative that is a potent intercalating antineoplastic agent. It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors. It is frequently used in combination with other antineoplastic agents in chemotherapy protocols. It produces consistent but acceptable myelosuppression and cardiotoxic effects. [PubChem]
OBJECTIVE Considering that global left ventricular systolic radial strain is a sensitive technique for the early detection of left ventricular dysfunction due to antineoplastics and the analysis of segmental myocardial contractility, we evaluated this technique for early detection of trastuzumab-related cardiotoxicity by comparing it with cardiac structural damage. METHODS Groups of six mice were injected with trastuzumab or doxorubicin, used either as single agents or in combination. Cardiac function was evaluated by transthoracic echocardiography measurements before and after treatment for 2 or 7 days, by using a Vevo 2100 high-resolution imaging system. After echocardiography, mice were euthanized, and hearts were processed for histological evaluations, such as cardiac fibrosis, apoptosis, capillary density, and inflammatory response. RESULTS Trastuzumab-related cardiotoxicity was detected early by 2D strain imaging. Radial strain was reduced after 2 days in mice treated with trastuzumab alone
TY - JOUR. T1 - Cardiotoxicity with immune system targeting drugs. T2 - A meta-analysis of anti-PD/PD-L1 immunotherapy randomized clinical trials. AU - Rahouma, Mohamed. AU - Karim, Nagla Abdel. AU - Baudo, Massimo. AU - Yahia, Maha. AU - Kamel, Mohamed. AU - Eldessouki, Ihab. AU - Abouarab, Ahmed. AU - Saad, Ihab. AU - Elmously, Adham. AU - Gray, Katherine D.. AU - Ghaly, Galal. AU - Gaber, Ola. AU - Kamal, Mona. AU - A Hassan, Ayah. AU - Rahouma, Mostafa. AU - DAscenzo, Fabrizio. AU - Morris, John. AU - Mohamed, Abdelrahman. AU - Girardi, Leonard. AU - Gaudino, Mario. PY - 2019/5/15. Y1 - 2019/5/15. N2 - Background: With antiprogrammed death receptor-1 (anti-PD-L1) therapy, a recent meta-analysis reported higher incidence of cutaneous, endocrine and gastrointestinal complications especially with dual anti-PD-L1 immunotherapy (IMM). Methods: Our primary outcome was assessment of all cardiotoxicity grades in IMM compared with different treatments, thus a systemic review and a meta-analysis on ...
Metabolic Syndrome clinical trial. Clinical trial for Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium.
Cardio-oncology is an emerging field of cardiology that focuses on cardiovascular diseases in patients with cancer. The classic cardio-oncology paradigm is the prevention, diagnosis and treatment of cardiotoxicity resulting from chemotherapy and/or radiotherapy. Diagnosis and treatment of primary and metastatic cardiac tumours as well as cardiac amyloidosis can be considered less classical cardio-oncology objectives.
Training set will consist of sera of 30 patients who has reached an end point. Training set will be sequenced using next generation sequencing.. Training set will be used to derive a miRNA signature capable of separating early cardiotoxicity patients from healthy ones. MiRNA signature will be validated using validation set. ...
At any time during the study, if your doctor thinks it is necessary, you will have an ECG and/or ECHO or MUGA scan.. If you stop receiving chemotherapy during your participation in this study, you will still be asked to complete the above tests and procedures listed at the 12-month (end-of-study visit) visit. Other tests and procedures scheduled during the study may not be performed because you are no longer receiving chemotherapy treatment. Your study doctor and the research staff will go over this information with you if this happens.. Research Test Results:. The primary biomarkers being tested in this study are the BNP and TnI. Both the BNP and TnI look at the function of your heart. The BNP and TnI will both be tested at MD Anderson.. The results of the biomarker tests will be kept separately from your other tests results, and will not affect your treatment in any way. The only reason your biomarker test results would be shared with your cancer doctor would be if the study doctor thinks the ...
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Centers RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.. ...
Specific target organ toxicity - single exposure : Not available Ingredient disclosure. Comments: This classification comes from an automated conversion of the classification established under the Controlled Products Regulations. The complete classification under the Hazardous Products Regulations will be determined at a later date.. ...
Technology Appraisal Guidance No. 446. Source: National Institute for Health and Care Excellence. 1. Guidance. 1.1 Brentuximab vedotin is recommended as an option for treating CD30-positive Hodgkin lymphoma in adults, only if:. they have relapsed or refractory disease after autologous stem cell transplant and. the company provides brentuximab vedotin at the price agreed with NHS England in the commercial access agreement.. 1.2 Brentuximab vedotin is recommended for use within the Cancer Drugs Fund as an option for treating CD30-positive Hodgkin lymphoma in adults, only if:. ...
Trastuzumab is a drug used for the treatment of metastatic breast cancer patients. Due to blockage of the human epidermal growth factor receptor 2 signaling in cardiac myocytes, cardiotoxicity has been observed. There are many studies that investigated risk factors for trastuzumab-induced cardiotoxicity, but no study has been published for factors on the time to cardiotoxicity. This study aimed to investigate the factors for the time to occur trastuzumab-induced cardiotoxicity. From January 2014 to December 2015, a retrospective study was performed with breast cancer patients who were treated with trastuzumab. Associations between presence of and time to cardiotoxicity and various factors were analyzed. Based on multivariate models, it was found that baseline left ventricular ejection fraction (LVEF) < 62.5% (AHR 5.96, 95% CI 2543-13.95) and anthracycline-based chemotherapy (AHR 7.90, 95% CI 1.05-59.71) were significant factors for time to cardiotoxicity after adjusting other confounding ...
This manuscript describes a detailed protocol to induce acute skeletal muscle regeneration in adult mice and subsequent manipulations...
Brentuximab vedotin - Intravenous : Brentuximab vedotin is used on its own or together with other medicines to treat cancer of the blood and lymph tissue.
The goal of this clinical research study is learn more about the safety of SGN-35 (brentuximab vedotin) in patients who participated in 2009-0851, were on placebo, and whose HL has gotten worse. Another goal of this study is to allow other patients with HL and ALCL whose disease has come back or is not getting better on another treatment, access to brentuximab vedotin.
I have read the article by Cardinale and colleagues1 with great interest and congratulate the authors for the completion of a burdensome work and the excellent presentation of their results. As the authors have correctly stated, early preclinical cardiac injury should be looked for soon after anthracycline treatment to effectively treat this disorder from its onset, before its overt clinical expression. However, I would like to point out one aspect that needs further clarification. The authors have reported that the overall incidence of cardiotoxicity is 9%. Previous researches have reported that anthracycline promotes cancer cell death via regulator of G-protein signaling 6 (RGS6)-mediated activation of ataxia telangiectasia-mutated serine/threonine protein kinase and the resultant upregulation of tumor suppressor p53, leading to an apoptosis pathway underlying its cytotoxic activity. The ability of RGS6 to promote p53 activation in response to anthracycline is independent of RGS6 interaction ...
The drug being tested in this study is called brentuximab vedotin. Brentuximab vedotin is being tested to treat pediatric participants who have advanced stage, newly diagnosed, classical CD30+ HL. This study will assess the safety, tolerability, and anti-tumor activity, as well as recommended dose of brentuximab vedotin in combination with a multiagent chemotherapy regimen that is based on a current standard of care (SOC) first-line treatment regimen for newly diagnosed HL. The study will enroll approximately 55 evaluable participants. The study will be conducted in 2 phases, Phase 1 and Phase 2. Phase 1 study will enroll up to 12 participants to determine the recommended dose. Once the recommended dose is identified additional participants will be enrolled into phase 2 so that the total number of evaluable participants will be approximately 55, including participants treated at recommended dose in Phase 1. Participants will be enrolled in the following 2 dose Cohorts: • Brentuximab vedotin 48 ...
Common AEs associated with brentuximab vedotin, such as peripheral neuropathy and neutropenia, are often manageable with modifications to dose and schedule.
Seattle Genetics Highlights Updated Progression-Free Survival and Overall Survival Data from ADCETRIS® (Brentuximab Vedotin) Frontline PTCL Phase 1 Clinical Trial at the ESMO 2014 Congress
City of Hope research-led study reports on five-year survival data, suggests that the targeted therapy brentuximab vedotin (BV) should be standard of care for patients with relapsed or treatment-resistant Hodgkin lymphoma.
Seattle Genetics Reports Data from Phase I Trial of ADCETRIS ® (Brentuximab Vedotin) in Front-line Mature T-Cell Lymphomas (MTCL) -100 Percent Objective Response Rate, Including 88 Percent Complete Remissions, in Newly Diagnosed MTCL Patients
Adult patients with CD30+ relapsed/refractory (R/R) Hodgkin Lymphoma (HL) after ASCT - National Institute for Health and Care Excellence (NICE) recommend long-term funding for brentuximab vedotin
In this study, we have shown that Id-mutant mice, unlike Id3-null mice, display a muscle regeneration phenotype using the cardiotoxin-induced TA muscle regeneration paradigm. The Id1 and Id3 proteins were markedly upregulated in the injured skeletal muscle of WT mice within 24 h, as were BMPR-II and pSmad1/5/8. Hindlimb injection of the BMP antagonist Noggin reduced the amounts of pSmad1/5/8 and both Id1 and Id3 at 24 h after cardiotoxin injury, suggesting that BMP signaling was responsible for their expression. These proteins were also expressed in the satellite cell-derived myogenic cell line C2C12 (3) when actively proliferating as myoblasts, but were all reduced on differentiation into myotubes. Immunofluorescent microscopy revealed that pSmad1/5/8, Id1, and Id3 were all detectable in the nuclei of many Pax7+ myoblasts in the injured mouse hindlimb at day 3 post-cardiotoxin injection. Finally, we showed that the Id-mutant mice, but not Id3-null mice, displayed a reduced number of ...
5-Fluorouracil (5-FU) is a commonly used anti-neoplastic agent. 5-FU has been not uncommonly associated with cardiotoxicity, although the many potentially causative mechanisms are yet to be established. Here, we present the case of a 61-year-old gemstone miner who developed symptomatic sinus bradycardia while receiving a continuous 5-FU infusion combined with radiotherapy for locally advanced rectal cancer. This dysrhythmia is an unusual type of 5-FU toxicity, our case being the second described. We review the actions of 5-FU and the various proposed mechanisms of its cardiotoxic effects ...
A paper published in 2011 indicates that taking two 220 mg naproxen tablets every day after age 70 substantially diminishes the development of Alzheimers disease, but only in asymptomatic individuals after two to three years on this regimen. By contrast, NSAIDs including naproxen had an adverse effect on patients with signs of AD pathogenesis, including those at the very early stages of cognitive impairment. Unfortunately, this trial (ADAPT) was not continued as long as it should have been because of health concerns about the cardiotoxic effects of one of the NSAIDs undergoing testing (celecoxib, Celebrex). However, clearly anyone with a family history of early-onset Alzheimers disease or over the age of 60 should definitely consider taking daily naproxen as a preventive measure as long as no cognitive defects are already apparent, and they have the consent of their physician. Naproxen has a good overall safety profile and is available over the counter in the United States (Aleve). However, ...
TY - JOUR. T1 - Adult rat myocardial slices. T2 - A tool for studies of comparative cardiotoxicity. AU - Parrish, A. R.. AU - Dorr, Robert T. AU - Gandolfi, A Jay. AU - Brendel, K.. PY - 1994. Y1 - 1994. N2 - The applicability of myocardial slices in comparative cardiotoxicity studies was investigated using the known cardiotoxicants allylamine (AAM) and doxorubicin (DOX). Precision-cut adult rat myocardial slices are a recently developed in vitro system. Previously, it has been demonstrated that myocardial slices are viable for up to 24 hr in organ culture. Myocardial slices exhibited a concentration- and time-dependent loss of viability in response to exposure to AAM or DOX (10-7, 10-6 or 10-5 m) during 24 hr in culture, as assessed by biochemical parameters including protein synthesis, ATP content, lipid peroxidation and the loss of the cytosolic enzyme creatine kinase. Protein synthesis and ATP content were sensitive indicators of slice viability, while lipid peroxidation was affected only by ...
1.Sánchez G, Cervantes G y Maldonado J. Linfomas No Hodgkin. Med Int Mex 2004; 20: 111-23. 2.Estrada D, Rajdev L and Sparado J. Lymphoma, Non-Hodgkin. Emedicine. Last Updated: June 24, 2004. 3.Ng R, Better N, Green MD. Anticancer agents and cardiotoxicity. Semin Oncol. 2006; 33 (1): 2-14. 4.Youssef G, Links M. The prevention and management of cardiovascular complications of chemotherapy in patients with cancer. Am J Cardiovasc Drugs. 2005; 5 (4): 233-43. 5.Pasca A, Pereiro G, Mansilla S y Lastiri H. Toxicidad miocardiaca por antraciclinas. Rev Fed Arg Cardiol 2000; 29:319-325. 6.Suter T and Meier B. Detection of anthracycline- induced cardiotoxicity: is there light at the end of the tunnel?. Editorial. Annals of Oncology. 2002; 13: 647-649. 7.Cvetkovic RS, Scott LJ. Dexrazoxane a review of its use for cardioprotection during anthracycline chemotherapy. Drugs. 2005; 65 (7): 1005-24. 8.Gianni L, Haerman E, Lipshultz S, Minotti G, sarvazyan N and Sawyer D.Anthracycline Cardiotoxicity: From Bench ...
There are many possible causes of cardiac toxicity. In cancer patients, cardiac toxicity may be caused by radiation to the chest and chemotherapy drugs.
Explore more about content imaging systems designed to assess cytotoxic effect of compounds on pertinent human cardiac cells, derived from induced pluripotent stem cells.
A session at the 64th Annual Scientific Session of the American College of Cardiology evaluated the cardiotoxic outcomes of treatment in cancer survivors.
MYTH: Synthroid (synthetic thyroid or T4, Thyroxine) works and is more effective than thyroid glandular.The truth: Synthroid is cardiotoxic, shrinks...
From our friends at GOOD: How I Became My Own Mentor in a Freelance Economy http://www.good.is/post/hustlin-how-i-became-my-own-mentor-in-a-freelance-economy/
... (CTX III, also known as cytotoxin 3) is a sixty amino-acid polypeptide toxin from the Taiwan Cobra Naja atra. ... Yang SH, Chien CM, Lu MC, Lu YJ, Wu ZZ, Lin SR (July 2005). "Cardiotoxin III induces apoptosis in K562 cells through a ...
... and cardiotoxins. Two forms of "cytotoxin II" (cardiotoxin) were found in the venom of this species. The crude venom of this ... Its venom consists mainly of postsynaptic neurotoxins and cardiotoxins. Four cardiotoxin-analogues I, II, III, and IV, account ... The venom of this species also contains myotoxins and cardiotoxins. The median lethal dose (LD50) is 0.28-0.33 mg per gram of ... Research has shown its venom is purely a neurotoxin, with no apparent necrotizing components and no cardiotoxins. These snakes ...
Its venom consists of both neurotoxins and cardiotoxins. Symptoms of envenomation include swelling of the injection site, ...
Cardiotoxins represented 40% of the snake's venom protein, higher than sympatric cobras: N. sputatrix (35%), N. siamensis (30 ... The venom also consists of cardiotoxins and cytotoxins. Although the venom of the Equatorial spitting cobra (N. sumatrana) ...
Although cardiotoxins have been isolated in higher proportions from its venom than other mamba species, their role in toxicity ... Its venom consists of both neurotoxins and cardiotoxins. Symptoms of envenomation in humans include pain and swelling at the ... Other toxins of the three-finger family present include alpha-neurotoxin, cardiotoxins and fasciculins. Dendrotoxins are akin ...
... they also carry cardiotoxins and fasciculins. Other components may include calcicludine, which is a known component of the ...
Its venom consists mainly of postsynaptic neurotoxins and cardiotoxins. Four cardiotoxin-analogues I, II, III, and IV, account ... Cardiotoxin-analogue III and phospholipase A2" (PDF). Journal of Biological Chemistry. 256 (17): 9279-9282. doi:10.1016/S0021- ...
These cardiotoxins also often have generalized cytotoxic effects and are sometimes known as cytolysins. The protein targets in ... The cardiotoxin/cytolysin 3FTx subgroup has a somewhat different set of functionally significant residues due to its distinct ... Lee SC, Lin CC, Wang CH, Wu PL, Huang HW, Chang CI, Wu WG (July 2014). "Endocytotic routes of cobra cardiotoxins depend on ... Rajagopalan N, Pung YF, Zhu YZ, Wong PT, Kumar PP, Kini RM (November 2007). "Beta-cardiotoxin: a new three-finger toxin from ...
Fletcher, J. E.; Jiang, M.-S.; Gong, Q.-H.; Yudkowsky, M.L.; Wieland, S.J. (1991). "Effects of a cardiotoxin from Naja kaouthia ... The venom of this species also contains myotoxins and cardiotoxins. In case of intravenous injection the LD50 tested in mice is ...
Evidence that cardiotoxins are responsible for the corneal opacification syndrome". Clinical Toxicology 31, 45-62. doi: 10.3109 ... Spitting cobras have also modified their secretion so that the cardiotoxins are more injurious to eye membranes. Nelsen, D. R ...
The venom is mainly composed of neurotoxins, cardiotoxins, and possibly myotoxins. Victims of the sting have reported local ...
The 3FTx family consists of two major categories, neurotoxins and cardiotoxins. LNTX belongs to the neurotoxin family; other ...
O. histrionica, along with O. speciosa, produces cardiotoxins known as histrionicotoxins. These moderate to highly toxic ...
Cardiotoxins are the second most toxic venom while neurotoxins are the first". Circulation. 121 (5): 675-83. doi:10.1161/ ... Cardiotoxin III Batrachotoxin Heart failure Drug interaction Sishi, Balindiwe J. N. (2015-01-01), Hayat, M. A. (ed.), "Chapter ...
"Evidence showing an intermolecular interaction between KChIP proteins and Taiwan cobra cardiotoxins". Biochem. Biophys. Res. ...
However, the main components of its venom are cardiotoxins with cytotoxic activity. In fact, polypeptide cardiotoxins make up ... "Cytotoxic potency of cardiotoxin from Naja sputatrix: development of a new cytolytic assay". Biochemical Journal. 366 (1): 35- ... postsynaptic neurotoxins and polypeptide cardiotoxins, meaning although the venom may be potent, it may not be particularly ...
The taxine alkaloids are cardiotoxins with taxine B being the most active. Taxine alkaloids have no medical uses but Paclitaxel ...
"Evidence showing an intermolecular interaction between KChIP proteins and Taiwan cobra cardiotoxins". Biochemical and ...
"Evidence showing an intermolecular interaction between KChIP proteins and Taiwan cobra cardiotoxins". Biochem. Biophys. Res. ...
Members of the three-finger family include alpha-neurotoxin, cardiotoxins, fasciculins and mambalgins. The most toxic ...
The Indian cobra's venom mainly contains a powerful post-synaptic neurotoxin and cardiotoxin. The venom acts on the synaptic ... ISBN 81-901873-0-9. Achyuthan, K. E.; Ramachandran, L. K. (1981). "Cardiotoxin of the Indian cobra (Naja naja) is a ... one cardiotoxin and one muscarinic toxin), six snake venom metalloproteinases, one nerve growth factor, two venom Kunitz serine ...
Another large subfamily of 3FTx proteins is the cardiotoxins (also known as cytotoxins or cytolysins); this group is directly ...
The venom consists mainly of both pre-synaptic and post-synaptic neurotoxins, cardiotoxins, and fasciculins. The toxicity of ... Its venom is a highly potent mixture of rapid-acting presynaptic and postsynaptic neurotoxins (dendrotoxins), cardiotoxins and ...
Research has shown its venom is purely a neurotoxin, with no apparent necrotizing components and no cardiotoxins. These snakes ...
The compounds consist of neurotoxins, cardiotoxin, nephrotoxin, hemolytic toxic, phosphodiesterases, phospholipase, histamine, ...
The compounds consist of neurotoxins, cardiotoxin, nephrotoxin, hemolytic toxic, phosphodiesterases, phospholipase, histamine, ...
The company also licensed a cardiotoxin therapy for acute and chronic nephropathy in 2015. In January, 2015, Celtic Biotech ...
Fryklund, Linda; Eaker, David (July 1975). "Complete covalent structure of a cardiotoxin from the venom of Naja nigricollis ( ... and cardiotoxins. Bite symptoms include severe external hemorrhaging and tissue necrosis around the bite area and difficulty ...
The snake venom of Echis species consists mostly of four types of toxins: neurotoxins, cardiotoxins, hemotoxins, and cytotoxins ...
Other toxic components in some species comprise cardiotoxins and cytotoxins, which cause heart dysfunctions and cellular damage ...
Cardiotoxins. Toxins that have effects on the heart and vessels that lead to undesirable outcomes. ...
Cardiotoxins / pharmacology * Flecainide / pharmacology* * Heart Ventricles / drug effects* * Humans * In Vitro Techniques ...
CARDIOTOXINS IN THE VENOM OF THE BANDED KRAIT. (BUNGARUS FASCIATUS). WEN-CHAN(3 CxANa,l 2. Mux-Lnv. LEEI. and. TuNC-Bnv. Lol. ... et a1.,1977 ; Ros,:R~rs et a1.,1977) . For the long-chain cardiotoxins reported. in the present paper, the histidine and ... Table 1) . It is clear from Table 1 that all three cardiotoxins show significant activity,. although it is lowas compared with ... This was true for all three cardiotoxins. It seems reasonable to conclude that the. enzyme activity is intrinsic to these ...
Cobra Cardiotoxin Proteins. D23 - Biological Factors. Shiga-Like Toxin I. Shiga Toxin 1. ...
General: Cardiotoxins. Possibly present General: Necrotoxins. Not present General: Other Toxins. Unknown ...
For instance, you might see the word myotoxins: attack muscular tissues; cardiotoxins: attack the heart and circulatory system ...
Ive been around wild Crotalus for years and Im looking to get an atrox in the next couple of years, can I see some picture of your enclosures?
It releases cardiotoxin, and chemicals with vasodilatory properties … also releases a bit of adrenaline, which gets the heart ...
In addition, while recognized inhaled cardio-toxins are relatively uncommon and contribute modestly to risk, physical and ... exposure to traditional chemical cardiotoxins (TNT, Hg) is relatively uncommon and play a small attributive role in CVD; 3) ...
... exposure to cardiotoxins, or metabolic disorders other than DM. Her medications included lisinopril, hydrochlorthiazide, ...
Moreover the cardiotoxin dumps now when I consume sugars as well. I will open a thread on the matter soon. Otherwise I am ...
Myocarditis may be caused by many disorders (eg, infection, cardiotoxins, drugs, and systemic disorders such... read more or ...
Keywords: Anthracyclines, Cardiotoxicity, Cardiotoxins, Troponin I, Consensus, Pharmaceutical Preparations, Heart Failure, ...
Snake venom cardiotoxins and bee venom melittin activate phospholipase C activity in primary cultures of skeletal muscle. ... Membrane interactions of amphiphilic polypeptides mastoparan, melittin, polymyxin B, and cardiotoxin. Differential inhibition ... Mastoparan and polymyxin B were much less inhibitory (IC50, 10-20 microM), whereas melittin and cardiotoxin were similarly ... These studies do not support the suggestion that snake venom cardiotoxins and melittin selectively activate endogenous ...
Cardiotoxins. Dizziness. Dopamine. Eating. Heart Arrest. Hospital Records. Humans. Lidocaine. Medicine, East Asian Traditional ... Aconitine and its related alkaloids are known cardiotoxins with no therapeutic role in modern western medicine. We have studied ...
Crystallographic studies of snake venom proteins from Taiwan cobra (Naja naja atra). Cardiotoxin-analogue III and phospholipase ...
... in Tibialis Anterior muscle at 14 days after muscle injury with cardiotoxin injection is shown.. ...
... display advanced skeletal muscle development during embryogenesis and advanced skeletal muscle regeneration after cardiotoxin- ...
In vivo synergy of cardiotoxin and phospholipase A2 from the elapid snake Naja mossambica mossambica. Pierre E Bougis, P. ... Localization of the toxic site of Naja mossambica cardiotoxins: small synthetic peptides express an in vivo lethality. P. ... Monitoring the purification by high-performance liquid chromatography of cardiotoxins from Naja mossambica mossambica using ...
Abbreviations used in this paper: ctx, cardiotoxin; HMGB, high mobility group box; ICAM, intercellular adhesion molecule; IL, ... Abbreviations used in this paper: ctx, cardiotoxin; HMGB, high mobility group box; ICAM, intercellular adhesion molecule; IL, ... previously injected intramuscularly with cardiotoxin [ctx]), X chromosome-linked muscular dystrophy (mdx), and α-SG-null mice. ...
Further, to study regeneration in aged tissue, the authors induced muscle injury using cobra cardiotoxin (CTX). Samples made ...
Further work was conducted on mice where injury on the muscles of the anterior legs was induced with a cardiotoxin. As a result ...
Cardiotoxins - Preferred Concept UI. M0507197. Scope note. Agents that have a damaging effect on the HEART. Such damage can ... Induction of LONG QT SYNDROME or TORSADES DE POINTES has been the reason for viewing some drugs as cardiotoxins.. ... Induction of LONG QT SYNDROME or TORSADES DE POINTES has been the reason for viewing some drugs as cardiotoxins. ...
Cardiotoxin venom (substance). Code System Preferred Concept Name. Cardiotoxin venom (substance). Concept Status. Published. ...
Cobra Cardiotoxin Proteins. D23 - Biological Factors. Shiga-Like Toxin I. Shiga Toxin 1. ...
Cobra Cardiotoxin Proteins. D23 - Biological Factors. Shiga-Like Toxin I. Shiga Toxin 1. ...
Cobra Cardiotoxin Proteins. D23 - Biological Factors. Shiga-Like Toxin I. Shiga Toxin 1. ...
  • Neurotoxins, Haemotoxins, Cardiotoxins, and Cytotoxins are the main types of venom substances that are produced in venomous snakes, and both those types are known to be deadly for humans and many other animals. (differencebetween.com)
  • It's best known as a heart poison, but it's also a lethal nerve toxin (cardiotoxins and neurotoxins). (forensicfield.blog)
  • Aconitine and its related alkaloids are known cardiotoxins with no therapeutic role in modern western medicine. (koreamed.org)
  • For starters, both bufadienolide and cardenolide, the main toxins found in Kalanchoe, are a type of cardiotoxin. (thepracticalplanter.com)
  • Female mice homozygous for a knock-out allele display advanced skeletal muscle development during embryogenesis and advanced skeletal muscle regeneration after cardiotoxin-induced degeneration. (jax.org)
  • The black mamba's venom has painkilling proteins as potent as morphine and deadly neuro and cardiotoxins. (theafricangourmet.com)
  • Activity Anthopleurin-C is a potent cardiotoxin, which evokes a positive inotropic and chronotropic effect on mammalian heart muscle 1,2 . (alomone.com)
  • From stem to leaves, this concentrated amount of cardiotoxins can lead to both acute and chronic Kalanchoe poisoning if not treated immediately. (thepracticalplanter.com)
  • In order to better characterize the function of miR-206 in muscle remodelling, we induced acute muscle damage in control mice by injecting cardiotoxin (CTX) in the tibialis (TA) of c57bl mice. (unimi.it)
  • ofphospholipase AZ and totally unrelated to typical cobra cardiotoxins (LuandLo,1981). (9lib.co)
  • red) and laminin (green) in Tibialis Anterior muscle at 14 days after muscle injury with cardiotoxin injection is shown. (kyushu-u.ac.jp)
  • Further work was conducted on mice where injury on the muscles of the anterior legs was induced with a cardiotoxin. (enzolifesciences.com)
  • Induction of LONG QT SYNDROME or TORSADES DE POINTES has been the reason for viewing some drugs as cardiotoxins. (bvsalud.org)
  • cardiotoxins: attack the heart and circulatory system. (hubpages.com)
  • These cardiotoxins are deemed heart-arresting and the higher the dose, the stronger the effect will be on the pet's central nervous system. (thepracticalplanter.com)